Immune Profiling Articles & Analysis
11 news found
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an ...
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation ...
We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles ...
The acquisition follows Immunai's purchase in March of software firm Dropprint Genomics. Immunai's platform profiles immune cells via a combination of single-cell RNA-seq, cellular indexing of transcriptomes and epitopes by sequencing, or CITE-seq, VDJ-seq, and other methods. The company uses the profiles to build out its AMICA, which it is ...
ByImmunai
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. Since launching in 2018, the New York ...
ByImmunai
DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held ...
INOVIO is addressing the new COVID variants through evaluating the impact of newly circulating strains of the SARS-CoV-2 virus on the immune profile of the INO-4800 vaccine and developing next-generation, pan-COVID vaccine candidates whose design could potentially provide better protection against the known and currently unknown SARS-CoV-2 variants. ...
Developing a reliable T-cell diagnostic comes with specific technological challenges with solutions offered by the NEC Immune Profiler at NOI to cater for the global human population. “T-cells are known to play a central role for initial and long term immunity against viruses. ...
Immunai has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and treatment to examine the body’s response to stimulus. ...
ByImmunai
Richard Stratford, the entire team at NEC OncoImmunity and our colleagues in the NEC Group to adapt our NEC Immune Profiler technology from its current cancer focus and quickly make it applicable to infectious diseases to help deal with the COVID-19 threat. ...